exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087983 RNA Name: hsa-miR-28-5p RNA Type: miRNA Chromosome: chr3 Starnd: + Coordinate: Start Site(bp): 188688794 End Site(bp): 188688815 External Links: hsa-miR-28-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RTL8A chrX 135050932 135052196 - LYPD3 chr19 43460787 43465608 - RGMA chr15 93035273 93089204 - GLYR1 chr16 4803203 4847288 - E2F6 chr2 11444375 11466177 - PTPN23 chr3 47381011 47413435 + KCTD5 chr16 2682523 2709030 + GPCPD1 chr20 5544439 5611006 - ENSA chr1 150600851 150629612 - AMOTL2 chr3 134355874 134375479 - SSR2 chr1 156009048 156020951 - FAM102A chr9 127940582 127980989 - N4BP1 chr16 48538726 48620148 - CPSF2 chr14 92121969 92172145 + EZH1 chr17 42700275 42745049 - KIAA1522 chr1 32741830 32774970 + LONRF2 chr2 100271875 100322501 - MAPK1 chr22 21754500 21867680 - LASP1 chr17 38869859 38921770 + SMYD1 chr2 88067825 88113384 + NAPA chr19 47487637 47515091 - URGCP chr7 43875894 43926411 - SMG5 chr1 156249224 156282825 - DYRK1A chr21 37365573 37526358 + RTL8B chrX 135020513 135022542 - SLC31A1 chr9 113221544 113264492 + SEH1L chr18 12947133 12987536 + ZBTB7B chr1 155002630 155018522 + TUB chr11 8019244 8106112 + TEX261 chr2 70985942 70994873 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009065.4 chr16 2119207 2120248 + AC016876.2 chr17 7581964 7584086 - AC026362.1 chr12 122975320 122982907 + AC118758.3 chr7 56809214 56848800 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.